![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Target Class: WDR Disease Areas: Cancer and epigenetics Site: Toronto Status: Follow-up official |
||
Target Class: WDR Disease Areas: Signalling Site: Toronto Status: Counted |
||
Target Class: WDR Disease Areas: Signalling Site: Toronto Status: Counted |
||
Target Class: Ubiquitylation - E3 Ligases Disease Areas: Signalling Site: Toronto Status: Counted |
||
Target Class: Ubiquitylation - E3 Ligases Disease Areas: Signalling Site: Toronto Status: Counted |
||
Target Class: Miscellaneous Disease Areas: Signalling Site: Toronto Status: Counted |
||
Target Class: Methyl-lysine readers Disease Areas: Cancer and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: Ubiquitylation - E3 Ligases Disease Areas: Signalling Site: Toronto Status: Follow-up official |
||
Target Class: Disease Areas: SARS-COV-2 Site: Frankfurt Status: |
||
Target Class: Disease Areas: SARS-COV-2 Site: Frankfurt Status: |
||
Target Class: Disease Areas: SARS-COV-2 Site: Frankfurt Status: |
||
Target Class: Ubiquitylation - E3 Ligases, WDR Disease Areas: Signalling and cancer Site: Toronto Status: Counted |
||
Target Class: WDR Disease Areas: Cancer Site: Toronto Status: Counted |
||
Target Class: Methyl-lysine readers Disease Areas: Cancer and epigenetics Site: Toronto Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Cancer and epigenetics Site: Toronto Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Cancer and epigenetics Site: Toronto Status: Follow-up official |
||
Target Class: Miscellaneous Disease Areas: Cancer Site: Toronto Status: Counted |
||
Target Class: WDR Disease Areas: Signalling Site: Toronto Status: Counted |
||
Target Class: Miscellaneous Disease Areas: Cancer Site: Toronto Status: Counted |
||
Target Class: Miscellaneous Disease Areas: Signalling and cancer Site: Toronto Status: Follow-up official |
||
Target Class: Miscellaneous Disease Areas: Cancer and epigenetics Site: Toronto Status: Counted |
||
Target Class: Methyl-lysine readers Disease Areas: Cancer and epigenetics Site: Toronto Status: MedChem |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Toronto Status: MedChem |
||
Target Class: Methyl-lysine readers Disease Areas: Cancer and epigenetics Site: Toronto Status: Follow-up official |
||
Target Class: Protein Kinase/TKL Disease Areas: Cancer Site: Oxford Status: MedChem |
||
Target Class: Methyl-lysine readers Disease Areas: Cancer and epigenetics Site: Toronto Status: Counted |
||
Target Class: Methyl-lysine readers Disease Areas: Cancer and epigenetics Site: Toronto Status: MedChem |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Toronto Status: MedChem |
||
Target Class: Protein Kinase/TKL Disease Areas: Cancer Site: Oxford Status: MedChem |
||
Target Class: Protein Kinase/TKL Disease Areas: Cancer Site: Oxford Status: MedChem |
||
Target Class: Methyl-lysine readers Disease Areas: Cancer and epigenetics Site: Toronto Status: MedChem |
||
Target Class: Protein Kinase/TKL Disease Areas: Cancer Site: Oxford Status: MedChem |
||
Target Class: Chromatin Regulation, Transferases Disease Areas: Epigenetics Site: Toronto Status: Follow-up official |
||
Target Class: Oxidoreductases Disease Areas: Metabolism Site: Oxford Status: Counted |
||
Target Class: Methyl-lysine readers Disease Areas: Cancer and epigenetics Site: Toronto Status: MedChem |
||
Target Class: Protein Kinase/TKL Disease Areas: Cancer Site: Oxford Status: MedChem |
||
Target Class: Protein Kinase/CMGC Disease Areas: Site: Frankfurt Status: Follow-up not counted |
||
Target Class: Bromodomain Disease Areas: Cancer and epigenetics Site: Oxford Status: MedChem |
||
Target Class: Vesicle Transport Disease Areas: Cancer Site: Oxford Status: Counted |
||
Target Class: Vesicle Transport Disease Areas: Cancer Site: Oxford Status: Counted |
||
Target Class: Ubiquitin Related Biology Disease Areas: Cancer Site: Toronto Status: Follow-up official |
||
Target Class: Methyltransferases Disease Areas: Cancer Site: Toronto Status: Counted |
||
Target Class: Methyltransferases Disease Areas: Cancer and epigenetics Site: Toronto Status: Counted |
||
Target Class: WDR Disease Areas: Neurobiology Site: Toronto Status: Counted |
||
Human protein arginine methyltransferase 6, full-length, in complex with covalent inhibitor YS17-117 Target Class: Methyltransferases Disease Areas: Cancer and epigenetics Site: Toronto Status: MedChem |
||
Target Class: Methyltransferases Disease Areas: Cancer and epigenetics Site: Toronto Status: MedChem |
||
Target Class: Ubiquitin Related Biology Disease Areas: Cancer Site: Toronto Status: Counted |
||
Target Class: Methyl-lysine readers Disease Areas: Cancer and epigenetics Site: Toronto Status: Counted |
||
Target Class: Bromodomain Disease Areas: Parasitic disease Site: Toronto Status: Counted |
||
Target Class: Disease Areas: Site: Oxford Status: Official |
||
Target Class: Protein Kinase/CMGC Disease Areas: Site: Frankfurt Status: Not counted |
||
Target Class: Protein Kinase/CMGC Disease Areas: Site: Frankfurt Status: MedChem |
||
Target Class: Methyltransferases Disease Areas: Chromatin and epigenetics Site: Toronto Status: Follow-up official |
||
Target Class: Chromatin Regulation Disease Areas: Cancer and epigenetics Site: Toronto Status: Counted |
||
Target Class: Chromatin Regulation Disease Areas: Cancer and epigenetics Site: Toronto Status: Follow-up official |
||
Human 5-hydroxymethylcytosine binding ES cell specific, SRAP domain, cross-linked to DNA abasic site Target Class: RNA/DNA Processing/DNA-Repair Disease Areas: Cancer Site: Toronto Status: Counted |
||
Target Class: RNA/DNA Processing/DNA-Repair Disease Areas: Cancer Site: Toronto Status: Not counted |
||
Human 5-hydroxymethylcytosine binding ES cell specific, SRAP domain, in complex with 3' overhang DNA Target Class: RNA/DNA Processing/DNA-Repair Disease Areas: Cancer Site: Toronto Status: Counted |
||
Target Class: Protein Kinase/CMGC Disease Areas: Signalling and cancer Site: Frankfurt Status: Not counted |
||
Target Class: Cell Division Disease Areas: Cancer Site: Oxford Status: Follow-up not counted |
||
Target Class: Protein Kinase/TKL Disease Areas: Site: Oxford Status: Follow-up not counted |
||
Target Class: Methyltransferases Disease Areas: Cancer Site: Toronto Status: MedChem |
||
Target Class: Membrane proteins Disease Areas: Site: Oxford Status: Official |
||
Target Class: Methyl-lysine readers Disease Areas: Cancer and epigenetics Site: Toronto Status: Follow-up official |
||
Target Class: Ubiquitin Related Biology Disease Areas: Site: Oxford Status: Official |
||
Target Class: Deubiquitinating Enzymes - USP, Ubiquitin Related Biology Disease Areas: Signalling and cancer Site: Toronto Status: MedChem |
||
Target Class: Protein Kinase Disease Areas: Autophagy and cancer Site: Frankfurt Status: Official |
||
Target Class: Protein Kinase Disease Areas: Autophagy and cancer Site: Frankfurt Status: Follow-up official |
||
Target Class: Protein Kinase Disease Areas: Autophagy and cancer Site: Frankfurt Status: Follow-up official |
||
Target Class: Protein Kinase Disease Areas: Autophagy and cancer Site: Frankfurt Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Parasitic disease Site: Toronto Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Parasitic disease Site: Toronto Status: Counted |
||
Target Class: Protein Kinase/CMGC Disease Areas: Signalling and cancer Site: Frankfurt Status: Follow-up not counted |
||
Target Class: Protein Kinase/CMGC Disease Areas: Signalling and cancer Site: Frankfurt Status: Follow-up not counted |
||
Target Class: Bromodomain Disease Areas: Parasitic disease Site: Toronto Status: Follow-up official |
||
Target Class: Protein Kinase/STE Disease Areas: Site: Oxford Status: Follow-up not counted |
||
Target Class: SPINDLIN Disease Areas: Site: Oxford Status: Follow-up not counted |
||
Target Class: SPINDLIN Disease Areas: Site: Oxford Status: Follow-up not counted |
||
Target Class: WDR Disease Areas: Signalling and cancer Site: Toronto Status: Counted |
||
Target Class: Protein Kinase/STE Disease Areas: Site: Oxford Status: Follow-up not counted |
||
Target Class: Protein Kinase/STE Disease Areas: Site: Oxford Status: Follow-up not counted |
||
Target Class: Protein Kinase/STE Disease Areas: Site: Oxford Status: Follow-up not counted |
||
Target Class: YEATS Disease Areas: Cancer and epigenetics Site: Frankfurt Status: Follow-up official |
||
Crystal structure of MLLT1 (ENL) YEATS domain in complexed with compound 94 (a SGC iMLLT derivative) Target Class: YEATS Disease Areas: Cancer and epigenetics Site: Frankfurt Status: MedChem |
||
Target Class: Methyl-lysine readers Disease Areas: Cancer and epigenetics Site: Toronto Status: Counted |
||
Target Class: Ubiquitin Related Biology, Ubiquitylation - E3 Ligases Disease Areas: Cancer Site: Toronto Status: Counted |
||
Target Class: Methyltransferases Disease Areas: Chromatin and epigenetics Site: Toronto Status: Follow-up official |
||
Target Class: YEATS Disease Areas: Cancer and epigenetics Site: Frankfurt Status: MedChem |
||
Target Class: YEATS Disease Areas: Cancer and epigenetics Site: Frankfurt Status: MedChem |
||
Target Class: YEATS Disease Areas: Cancer and epigenetics Site: Frankfurt Status: MedChem |
||
Target Class: YEATS Disease Areas: Cancer and epigenetics Site: Frankfurt Status: MedChem |
||
Target Class: YEATS Disease Areas: Cancer and epigenetics Site: Frankfurt Status: Follow-up not counted |
||
Target Class: Kinase-TK Disease Areas: Site: Oxford Status: Follow-up not counted |
||
Target Class: Bromodomain Disease Areas: Parasitic disease Site: Toronto Status: Counted |
||
Target Class: Methyltransferases Disease Areas: Chromatin and epigenetics Site: Toronto Status: Follow-up official |
||
Target Class: Miscellaneous Disease Areas: Signalling Site: Toronto Status: Follow-up official |
||
Target Class: Protein Kinase Disease Areas: Site: Oxford Status: Official |
||
Target Class: Protein Kinase/CMGC Disease Areas: Cancer Site: Oxford Status: MedChem |
||
Target Class: Protein Kinase/CMGC Disease Areas: Cancer Site: Oxford Status: MedChem |
||
Target Class: Miscellaneous Disease Areas: Signalling Site: Toronto Status: Not counted |
||
Target Class: Membrane proteins Disease Areas: Site: Oxford Status: Official |
||
Target Class: Deubiquitinating Enzymes - USP, Ubiquitin Related Biology Disease Areas: Signalling and cancer Site: Toronto Status: MedChem |
||
Target Class: Ubiquitin Related Biology, Ubiquitylation - E3 Ligases Disease Areas: Site: Oxford Status: Follow-up official |
||
Target Class: Deubiquitinating Enzymes - USP, Ubiquitin Related Biology Disease Areas: Signalling and cancer Site: Toronto Status: MedChem |
||
Target Class: Methyltransferases Disease Areas: Cancer and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: Kinase-TK Disease Areas: Site: Oxford Status: |
||
Target Class: Methyltransferases Disease Areas: Signalling Site: Toronto Status: Follow-up official |
||
Target Class: Protein Kinase/STE Disease Areas: Site: Oxford Status: Follow-up not counted |
||
Target Class: NUDIX Disease Areas: Site: Oxford Status: Follow-up official |
||
Target Class: Protein Kinase/Other Disease Areas: Cancer Site: Oxford Status: Counted |
||
Target Class: Protein Kinase/Other Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Protein Kinase/Other Disease Areas: Cancer Site: Oxford Status: MedChem |
||
Target Class: Disease Areas: Metabolism Site: Oxford Status: Follow-up official |
||
Target Class: Oxidoreductases Disease Areas: Site: Oxford Status: |
||
Target Class: Oxidoreductases Disease Areas: Site: Oxford Status: Follow-up not counted |
||
Target Class: Oxidoreductases Disease Areas: Site: Oxford Status: |
||
Target Class: Oxidoreductases Disease Areas: Site: Oxford Status: Follow-up not counted |
||
Target Class: Oxidoreductases Disease Areas: Site: Oxford Status: Follow-up not counted |
||
Target Class: Disease Areas: Site: Oxford Status: |
||
Target Class: Cell Division Disease Areas: Cancer Site: Oxford Status: Follow-up not counted |
||
Target Class: Cell Division Disease Areas: Cancer Site: Oxford Status: Follow-up not counted |
||
Target Class: Cell Division Disease Areas: Site: Oxford Status: Follow-up not counted |
||
Target Class: Cell Division Disease Areas: Cancer Site: Oxford Status: Follow-up not counted |
||
Target Class: Cell Division Disease Areas: Cancer Site: Oxford Status: Follow-up not counted |
||
Target Class: Cell Division Disease Areas: Cancer Site: Oxford Status: Follow-up not counted |
||
Target Class: Cell Division Disease Areas: Cancer Site: Oxford Status: Follow-up not counted |
||
Target Class: Protein Kinase/TKL Disease Areas: Site: Oxford Status: |
||
Target Class: Protein Kinase/TKL Disease Areas: Site: Oxford Status: |
||
Target Class: Protein Kinase/CMGC Disease Areas: Signalling and cancer Site: Frankfurt Status: Follow-up not counted |
||
Target Class: Miscellaneous Disease Areas: Chromatin and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: Ubiquitin Related Biology, Ubiquitylation - E3 Ligases Disease Areas: Site: Oxford Status: Official |
||
Target Class: Bromodomain Disease Areas: Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Site: Oxford Status: Follow-up official |
||
Target Class: WDR Disease Areas: Signalling and cancer Site: Toronto Status: Official |
||
Target Class: Bromodomain Disease Areas: Parasitic disease Site: Status: Counted |
||
Target Class: Protein Kinase/CMGC Disease Areas: Signalling and cancer Site: Frankfurt Status: Follow-up not counted |
||
Target Class: Methyltransferases Disease Areas: Cancer and epigenetics Site: Toronto Status: MedChem |
||
Target Class: Miscellaneous Disease Areas: Chromatin and epigenetics Site: Toronto Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer and epigenetics Site: Toronto Status: Counted |
||
Target Class: Disease Areas: Site: Oxford Status: Official |
||
Target Class: Bromodomain Disease Areas: Site: Oxford Status: Follow-up not counted |
||
Target Class: Bromodomain Disease Areas: Site: Oxford Status: Follow-up not counted |
||
Target Class: Bromodomain Disease Areas: Site: Oxford Status: Follow-up not counted |
||
Target Class: Bromodomain Disease Areas: Site: Oxford Status: Follow-up not counted |
||
Target Class: Bromodomain Disease Areas: Site: Oxford Status: Follow-up not counted |
||
Target Class: Miscellaneous Disease Areas: Cancer and epigenetics Site: Toronto Status: Follow-up official |
||
Target Class: Membrane proteins Disease Areas: Neurobiology Site: Oxford Status: Follow-up official |
||
Target Class: Protein Kinase/TKL Disease Areas: Cancer Site: Oxford Status: MedChem |
||
Target Class: Miscellaneous Disease Areas: Cancer and epigenetics Site: Toronto Status: Counted |
||
Target Class: Methyltransferases Disease Areas: Cancer and epigenetics Site: Toronto Status: Counted |
||
Target Class: Cell Division Disease Areas: Cancer Site: Oxford Status: Follow-up not counted |
||
Target Class: Ubiquitin Related Biology, Ubiquitylation - E3 Ligases Disease Areas: Signalling and metabolism Site: Toronto Status: Counted |
||
Target Class: Ubiquitin Related Biology, Ubiquitylation - E3 Ligases Disease Areas: Signalling and metabolism Site: Toronto Status: Counted |
||
Target Class: Miscellaneous Disease Areas: Chromatin and epigenetics Site: Toronto Status: Counted |
||
Target Class: Miscellaneous Disease Areas: Cancer and epigenetics Site: Toronto Status: Follow-up official |
||
Target Class: Miscellaneous Disease Areas: Cancer and epigenetics Site: Toronto Status: Follow-up official |
||
Target Class: Miscellaneous Disease Areas: Cancer and epigenetics Site: Toronto Status: Counted |
||
Target Class: Protein Kinase/Other Disease Areas: Cancer Site: Oxford Status: Counted |
||
Target Class: Protein Kinase/Other Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Disease Areas: Site: Oxford Status: Official |
||
Target Class: Bromodomain Disease Areas: Parasitic disease Site: Toronto Status: Follow-up official |
||
Target Class: Methyltransferases Disease Areas: Chromatin and epigenetics Site: Toronto Status: Counted |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Toronto Status: MedChem |
||
Target Class: Protein Kinase/Other Disease Areas: Site: Oxford Status: |
||
Target Class: WDR Disease Areas: Cancer and epigenetics Site: Status: Follow-up official |
||
Target Class: WDR Disease Areas: Cancer and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: Methyltransferases Disease Areas: Cancer and epigenetics Site: Toronto Status: MedChem |
||
Target Class: Disease Areas: Site: Oxford Status: |
||
Target Class: Disease Areas: Cancer and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: Methyltransferases Disease Areas: Cancer and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: Methyltransferases Disease Areas: Cancer and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: Methyltransferases Disease Areas: Cancer and epigenetics Site: Toronto Status: Counted |
||
Target Class: Methyltransferases Disease Areas: Cancer and epigenetics Site: Toronto Status: Follow-up official |
||
Target Class: Kinase-Other Disease Areas: Site: Oxford Status: |
||
Target Class: Protein Kinase/STE Disease Areas: Cancer Site: Oxford Status: MedChem |
||
Target Class: Ubiquitin Related Biology, Ubiquitylation - E3 Ligases Disease Areas: Signalling and epigenetics Site: Toronto Status: Counted |
||
Target Class: Demethylase/Methyl-Lysine Reader, PHD domain Disease Areas: Cancer Site: Oxford Status: |
||
Target Class: Demethylase/Methyl-Lysine Reader, PHD domain Disease Areas: Cancer Site: Oxford Status: |
||
Target Class: Demethylase/Methyl-Lysine Reader, PHD domain Disease Areas: Cancer Site: Oxford Status: |
||
Target Class: Demethylase/Methyl-Lysine Reader, PHD domain Disease Areas: Cancer Site: Oxford Status: |
||
Target Class: Methyl-lysine readers Disease Areas: Signalling and cancer Site: Toronto Status: Follow-up official |
||
Target Class: Demethylase/Methyl-Lysine Reader, PHD domain Disease Areas: Cancer Site: Oxford Status: |
||
Target Class: Demethylase/Methyl-Lysine Reader, PHD domain Disease Areas: Cancer Site: Oxford Status: |
||
Target Class: Disease Areas: Neurobiology Site: Oxford Status: Official |
||
Target Class: Protein Kinase/Other Disease Areas: Site: Oxford Status: |
||
Target Class: Miscellaneous Disease Areas: Cancer and epigenetics Site: Toronto Status: Counted |
||
Target Class: Methyl-lysine readers Disease Areas: Cancer and epigenetics Site: Status: Follow-up not counted |
||
Target Class: Methyl-lysine readers Disease Areas: Cancer and epigenetics Site: Toronto Status: MedChem |
||
Target Class: Miscellaneous Disease Areas: Cancer Site: Toronto Status: Counted |
||
Target Class: Miscellaneous Disease Areas: Cancer Site: Toronto Status: Counted |
||
Target Class: Miscellaneous Disease Areas: Cancer Site: Toronto Status: Follow-up not counted |
||
Target Class: WDR Disease Areas: Cancer and epigenetics Site: Status: Follow-up official |
||
Target Class: Methyltransferases Disease Areas: Cancer and epigenetics Site: Toronto Status: Follow-up official |
||
Target Class: Methyltransferases Disease Areas: Chromatin and epigenetics Site: Toronto Status: Counted |
||
Target Class: Transferases Disease Areas: Chromatin and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: Methyltransferases Disease Areas: Chromatin and epigenetics Site: Toronto Status: MedChem |
||
Target Class: IMP/ABC Transporter Disease Areas: Metabolism Site: Oxford Status: Official |
||
Target Class: Transferases, Ubiquitin Related Biology Disease Areas: Cancer Site: Toronto Status: Follow-up official |
||
Target Class: Miscellaneous Disease Areas: Chromatin and epigenetics Site: Toronto Status: Counted |
||
Target Class: Miscellaneous Disease Areas: Chromatin and epigenetics Site: Toronto Status: Official |
||
Target Class: Methyltransferases Disease Areas: Chromatin and epigenetics Site: Toronto Status: Follow-up official |
||
Target Class: Protein Kinase Disease Areas: Parasitic disease Site: Toronto Status: Follow-up not counted |
||
Target Class: Protein Kinase Disease Areas: Parasitic disease Site: Toronto Status: Follow-up not counted |
||
Target Class: Protein Kinase Disease Areas: Parasitic disease Site: Toronto Status: Follow-up not counted |
||
Target Class: Protein Kinase Disease Areas: Parasitic disease Site: Toronto Status: Follow-up not counted |
||
Target Class: Protein Kinase Disease Areas: Parasitic disease Site: Status: Follow-up official |
||
Target Class: Methyltransferases Disease Areas: Cancer and epigenetics Site: Toronto Status: MedChem |
||
Target Class: RNA/DNA Processing/DNA-Repair Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: RNA/DNA Processing/DNA-Repair Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: RNA/DNA Processing/DNA-Repair Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: IMP/Enzyme Disease Areas: Neurobiology Site: Oxford Status: Follow-up official |
||
Target Class: Protein Kinase/TKL Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Protein Kinase/TKL Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Disease Areas: Signalling Site: Oxford Status: Official |
||
Target Class: Disease Areas: Metabolism Site: Oxford Status: Official |
||
Target Class: Protein Kinase/Other Disease Areas: Signalling Site: Oxford Status: Official |
||
Target Class: Protein Kinase/Other Disease Areas: Signalling Site: Oxford Status: Follow-up official |
||
Target Class: Protein Kinase/Other Disease Areas: Signalling Site: Oxford Status: Follow-up official |
||
Target Class: Protein Kinase/Other Disease Areas: Signalling Site: Oxford Status: Official |
||
Target Class: Protein Kinase/Other Disease Areas: Signalling Site: Oxford Status: Follow-up official |
||
Target Class: Protein Kinase/Other Disease Areas: Signalling Site: Oxford Status: Follow-up official |
||
Target Class: Oxidoreductases Disease Areas: Metabolism Site: Oxford Status: Follow-up official |
||
Target Class: Oxidoreductases Disease Areas: Metabolism Site: Oxford Status: Follow-up official |
||
Target Class: Oxidoreductases Disease Areas: Metabolism Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Parasitic disease Site: Toronto Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer and epigenetics Site: Oxford Status: MedChem |
||
Target Class: Bromodomain Disease Areas: Cancer and epigenetics Site: Oxford Status: MedChem |
||
Target Class: Bromodomain Disease Areas: Cancer and epigenetics Site: Oxford Status: MedChem |
||
Target Class: Bromodomain Disease Areas: Cancer and epigenetics Site: Oxford Status: MedChem |
||
Target Class: Bromodomain Disease Areas: Cancer and epigenetics Site: Oxford Status: MedChem |
||
Target Class: Disease Areas: Neurobiology Site: Oxford Status: Official |
||
Target Class: Ubiquitin Related Biology, Ubiquitylation - E3 Ligases Disease Areas: Metabolism Site: Oxford Status: Official |
||
Target Class: Ubiquitin Related Biology, Ubiquitylation - E3 Ligases Disease Areas: Metabolism Site: Oxford Status: Follow-up official |
||
Target Class: Miscellaneous Disease Areas: Chromatin and epigenetics Site: Toronto Status: Official |
||
Target Class: Methyl-lysine readers Disease Areas: Cancer Site: Toronto Status: Official |
||
Target Class: Ubiquitin Related Biology Disease Areas: Signalling Site: Toronto Status: Follow-up official |
||
Target Class: Oxidoreductases Disease Areas: Signalling Site: Toronto Status: Official |
||
Target Class: Deubiquitinating Enzymes - USP, Ubiquitin Related Biology Disease Areas: Signalling Site: Toronto Status: Official |
||
Target Class: Methyltransferases Disease Areas: Chromatin and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: Methyltransferases Disease Areas: Chromatin and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: Metabolic enzymes/Other Disease Areas: Metabolism Site: Oxford Status: Official |
||
Target Class: Protein Kinase/CMGC Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up not counted |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Protein Kinase/CMGC Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Protein Kinase/CMGC Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Signalling proteins Disease Areas: Metabolism Site: Toronto Status: Follow-up official |
||
Target Class: Phosphatases Disease Areas: Signalling Site: Oxford Status: Follow-up official |
||
Target Class: Transferases Disease Areas: Chromatin and epigenetics, Signalling Site: Toronto Status: Pending-Official Structure |
||
Target Class: Methyltransferases Disease Areas: Chromatin and epigenetics, Signalling Site: Toronto Status: Pending-Official Structure |
||
Target Class: Bromodomain, Ubiquitin Related Biology, Ubiquitylation - E3 Ligases Disease Areas: Chromatin and epigenetics Site: Oxford Status: Official |
||
Target Class: Miscellaneous Disease Areas: Metabolism Site: Oxford Status: Pending-Official Structure |
||
Target Class: Protein Kinase Disease Areas: Cancer Site: Oxford Status: Pending-Official Structure |
||
Target Class: Bromodomain Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Miscellaneous Disease Areas: Neurobiology Site: Oxford Status: Pending-Official Structure |
||
Target Class: Bromodomain Disease Areas: Chromatin and epigenetics, Parasitic disease Site: Toronto Status: Pending-Official Structure |
||
Target Class: NUDIX Disease Areas: Metabolism Site: Oxford Status: Pending-Official Structure |
||
Target Class: Miscellaneous Disease Areas: Neurobiology Site: Oxford Status: Pending-Official Structure |
||
Target Class: Methyltransferases Disease Areas: Cancer, Chromatin and epigenetics Site: Toronto Status: MedChem |
||
Target Class: Miscellaneous Disease Areas: Neurobiology Site: Oxford Status: Pending-Official Structure |
||
Target Class: Bromodomain Disease Areas: Cancer, Signalling Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Metabolism, Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: WDR Disease Areas: Cancer, Chromatin and epigenetics Site: Toronto Status: MedChem |
||
Target Class: Methyltransferases Disease Areas: Cancer, Chromatin and epigenetics, Neurobiology Site: Toronto Status: Follow-up not counted |
||
Target Class: Methyltransferases Disease Areas: Cancer, Chromatin and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: Methyl-lysine readers Disease Areas: Site: Oxford Status: Pending-Official Structure |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Chromatin and epigenetics, Parasitic disease Site: Toronto Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyltransferases Disease Areas: Chromatin and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: Methyltransferases Disease Areas: Cancer, Chromatin and epigenetics Site: Toronto Status: MedChem |
||
Target Class: Cell Division Disease Areas: Cancer Site: Oxford Status: Pending-Official Structure |
||
Target Class: WDR Disease Areas: Chromatin and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: WDR Disease Areas: Chromatin and epigenetics Site: Toronto Status: Follow-up official |
||
Target Class: Miscellaneous Disease Areas: Chromatin and epigenetics Site: Toronto Status: Pending-Official Structure |
||
Target Class: Miscellaneous Disease Areas: Chromatin and epigenetics Site: Toronto Status: Follow-up official |
||
Target Class: Miscellaneous Disease Areas: Neurobiology Site: Toronto Status: Pending - Official structure |
||
Target Class: Miscellaneous Disease Areas: Chromatin and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: Protein Kinase Disease Areas: Cancer, Metabolism, Signalling, Neurobiology Site: Oxford Status: Follow-up official |
||
Target Class: Protein Kinase Disease Areas: Cancer, Metabolism, Signalling, Neurobiology Site: Oxford Status: Follow-up official |
||
Target Class: Protein Kinase Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Protein Kinase Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: NUDIX Disease Areas: Metabolism Site: Oxford Status: Pending-Official Structure |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Parasitic disease Site: Toronto Status: Pending-Official Structure |
||
Target Class: Bromodomain Disease Areas: Parasitic disease Site: Toronto Status: Pending-Official Structure |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics, Signalling Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics, Signalling Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics, Signalling Site: Oxford Status: Follow-up official |
||
Target Class: Chromatin Regulation Disease Areas: Chromatin and epigenetics Site: Oxford Status: Pending-Official Structure |
||
Target Class: Methyltransferases Disease Areas: Cancer, Chromatin and epigenetics Site: Toronto Status: MedChem |
||
Target Class: NUDIX Disease Areas: Metabolism Site: Oxford Status: Pending-Official Structure |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Toronto Status: Follow-up official |
||
Target Class: IMP/Enzyme Disease Areas: Metabolism Site: Oxford Status: Official |
||
Target Class: Nucleotide metabolism, NUDIX Disease Areas: Metabolism Site: Oxford Status: Pending-Official Structure |
||
Target Class: Bromodomain Disease Areas: Parasitic disease Site: Toronto Status: Pending - Official structure |
||
Target Class: Miscellaneous Disease Areas: Site: Oxford Status: Pending - Official structure |
||
Target Class: Transferases Disease Areas: Chromatin and epigenetics Site: Toronto Status: Pending - Official structure |
||
Target Class: DExD-DExH RNA helicases Disease Areas: Cancer Site: Oxford Status: Pending-Official Structure |
||
Target Class: DExD-DExH RNA helicases Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: DExD-DExH RNA helicases Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: DExD-DExH RNA helicases Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Transferases, Ubiquitin Related Biology Disease Areas: Cancer Site: Toronto Status: MedChem |
||
Target Class: Ubiquitin Related Biology Disease Areas: Site: Toronto Status: MedChem |
||
Target Class: Methyl-lysine readers Disease Areas: Cancer, Chromatin and epigenetics Site: Toronto Status: Pending-Official Structure |
||
Target Class: Transferases, Ubiquitin Related Biology Disease Areas: Cancer Site: Toronto Status: MedChem |
||
Target Class: Transferases, Ubiquitin Related Biology Disease Areas: Cancer Site: Toronto Status: MedChem |
||
Target Class: Protein Kinase Disease Areas: Signalling Site: Oxford Status: Follow-up official |
||
Target Class: Oxidoreductases Disease Areas: Metabolism Site: Oxford Status: Pending-Official Structure |
||
Target Class: Oxidoreductases Disease Areas: Metabolism Site: Oxford Status: Pending-Official Structure |
||
Target Class: Protein Kinase Disease Areas: Cancer Site: Oxford Status: Pending-Official Structure |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics Site: Oxford Status: Pending-Official Structure |
||
Target Class: Protein Kinase Disease Areas: Site: Oxford Status: Follow-up official |
||
Target Class: Membrane proteins Disease Areas: Metabolism Site: Oxford Status: Pending-Official Structure |
||
Target Class: Bromodomain Disease Areas: Parasitic disease Site: Toronto Status: Pending-Official Structure |
||
Target Class: Methyltransferases Disease Areas: Cancer, Chromatin and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: Protein Kinase/Other Disease Areas: Cancer Site: Oxford Status: Pending-Official Structure |
||
Target Class: Protein Kinase Disease Areas: Parasitic disease Site: Toronto Status: Follow-up official |
||
Target Class: Miscellaneous Disease Areas: Cancer Site: Toronto Status: Pending-Official Structure |
||
Target Class: Miscellaneous Disease Areas: Cancer Site: Toronto Status: Pending-Official Structure |
||
Target Class: Oxidoreductases Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Protein Kinase Disease Areas: Parasitic disease Site: Toronto Status: Pending-Official Structure |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Toronto Status: Pending-Official Structure |
||
Target Class: Miscellaneous Disease Areas: Chromatin and epigenetics Site: Toronto Status: Pending-Official Structure |
||
Target Class: Protein Kinase Disease Areas: Signalling Site: Oxford Status: Follow-up official |
||
Target Class: Protein Kinase Disease Areas: Signalling Site: Oxford Status: Follow-up official |
||
Target Class: Protein Kinase Disease Areas: Signalling Site: Oxford Status: Pending-Official Structure |
||
Target Class: Oxidoreductases Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Pending-Official Structure |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Oxidoreductases Disease Areas: Site: Oxford Status: Follow-up official |
||
Target Class: Transferases Disease Areas: Metabolism Site: Oxford Status: Pending-Official Structure |
||
Target Class: Methyltransferases Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyltransferases Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyltransferases Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyltransferases Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Oxidoreductases Disease Areas: Site: Oxford Status: Follow-up official |
||
Target Class: Oxidoreductases Disease Areas: Site: Oxford Status: Follow-up official |
||
Target Class: Oxidoreductases Disease Areas: Site: Oxford Status: Follow-up official |
||
Target Class: Oxidoreductases Disease Areas: Site: Oxford Status: Follow-up official |
||
Target Class: Oxidoreductases Disease Areas: Site: Oxford Status: Follow-up official |
||
Target Class: Oxidoreductases Disease Areas: Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics, Signalling Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics, Signalling Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics, Signalling Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: Methyltransferases Disease Areas: Chromatin and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics, Signalling Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics, Signalling Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics, Signalling Site: Oxford Status: Follow-up official |
||
Target Class: Ubiquitin Related Biology, Ubiquitylation - E3 Ligases Disease Areas: Signalling Site: Toronto Status: Official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics, Signalling Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyltransferases Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics, Signalling Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics, Signalling Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics, Signalling, Neurobiology Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics, Signalling, Neurobiology Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics, Signalling, Neurobiology Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics, Signalling, Neurobiology Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics, Signalling, Neurobiology Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics, Signalling, Neurobiology Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics, Signalling, Neurobiology Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Parasitic disease Site: Toronto Status: Pending-Official Structure |
||
Target Class: Protein Kinase Disease Areas: Signalling Site: Oxford Status: Follow-up official |
||
Target Class: Protein Kinase Disease Areas: Signalling Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics, Signalling, Neurobiology Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics, Signalling, Neurobiology Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics, Signalling, Neurobiology Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics, Signalling, Neurobiology Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics, Signalling Site: Oxford Status: Follow-up official |
||
Target Class: Transferases Disease Areas: Signalling Site: Toronto Status: Pending-Official Structure |
||
Target Class: Oxidoreductases Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Oxidoreductases Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Oxidoreductases Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: Methyl-lysine readers Disease Areas: Cancer, Chromatin and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: Methyl-lysine readers Disease Areas: Cancer, Chromatin and epigenetics Site: Toronto Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Miscellaneous Disease Areas: Cancer, Chromatin and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: Miscellaneous Disease Areas: Cancer, Chromatin and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: Miscellaneous Disease Areas: Cancer, Chromatin and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: Miscellaneous Disease Areas: Cancer, Chromatin and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: Bromodomain Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyltransferases Disease Areas: Cancer, Chromatin and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: Methyltransferases Disease Areas: Cancer Site: Toronto Status: Follow-up not counted |
||
Target Class: Methyltransferases Disease Areas: Cancer Site: Toronto Status: Follow-up not counted |
||
Target Class: Methyltransferases Disease Areas: Cancer Site: Toronto Status: Follow-up not counted |
||
Target Class: Non-protein Kinase Disease Areas: Metabolism, Signalling Site: Toronto Status: Pending-Official Structure |
||
Target Class: Methyltransferases Disease Areas: Cancer Site: Toronto Status: Pending-Official Structure |
||
Target Class: Methyltransferases Disease Areas: Cancer Site: Toronto Status: Follow-up official |
||
Target Class: Methyltransferases Disease Areas: Cancer Site: Toronto Status: Follow-up not counted |
||
Target Class: Protein Kinase Disease Areas: Parasitic disease Site: Toronto Status: Follow-up official |
||
Target Class: Protein Kinase Disease Areas: Parasitic disease Site: Toronto Status: Follow-up not counted |
||
Target Class: Protein Kinase Disease Areas: Parasitic disease Site: Toronto Status: Follow-up not counted |
||
Target Class: Amino oxidases Disease Areas: Metabolism Site: Oxford Status: Pending-Official Structure |
||
Target Class: Protein Kinase Disease Areas: Parasitic disease Site: Toronto Status: Follow-up not counted |
||
Target Class: Protein Kinase Disease Areas: Parasitic disease Site: Toronto Status: Follow-up not counted |
||
Target Class: Amino oxidases Disease Areas: Metabolism Site: Oxford Status: Pending-Official Structure |
||
Target Class: Bromodomain Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Protein Kinase Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Chromatin and epigenetics, Parasitic disease Site: Toronto Status: Pending-Official Structure |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Miscellaneous Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Miscellaneous Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Miscellaneous Disease Areas: Metabolism Site: Oxford Status: Follow-up official |
||
Target Class: Miscellaneous Disease Areas: Metabolism Site: Oxford Status: Follow-up official |
||
Target Class: Ubiquitin Related Biology, Ubiquitylation - E3 Ligases Disease Areas: Metabolism Site: Oxford Status: Official |
||
Target Class: Phosphatases Disease Areas: Signalling Site: Toronto Status: Follow-up official |
||
Target Class: Protein Kinase Disease Areas: Parasitic disease Site: Toronto Status: Follow-up official |
||
Target Class: Miscellaneous Disease Areas: Cancer Site: Toronto Status: Pending-Official Structure |
||
Target Class: Bromodomain Disease Areas: Site: Toronto Status: Pending-Official Structure |
||
Target Class: Ubiquitin Related Biology, Ubiquitylation - E3 Ligases Disease Areas: Cancer Site: Toronto Status: Official |
||
Target Class: Ubiquitin Related Biology, Ubiquitylation - E3 Ligases Disease Areas: Cancer Site: Toronto Status: Official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Toronto Status: Pending-Official Structure |
||
Target Class: Membrane proteins Disease Areas: Drug metabolism and toxicology Site: Oxford Status: Pending-Official Structure |
||
Target Class: Miscellaneous Disease Areas: Signalling, Neurobiology Site: Toronto Status: Pending-Official Structure |
||
Target Class: Bromodomain Disease Areas: Parasitic disease Site: Toronto Status: Pending-Official Structure |
||
Target Class: Methyl-lysine readers Disease Areas: Cancer, Chromatin and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: Miscellaneous Disease Areas: Metabolism Site: Oxford Status: Pending - Official structure |
||
Target Class: Oxidoreductases Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Oxidoreductases Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Site: Oxford Status: Follow-up official |
||
Target Class: Oxidoreductases Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Protein Kinase Disease Areas: Cancer, Signalling, Neurobiology Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Oxford Status: Pending - Official structure |
||
Target Class: Oxidoreductases Disease Areas: Site: Oxford Status: Follow-up official |
||
Target Class: Methyl-lysine readers Disease Areas: Site: Oxford Status: Pending - Official structure |
||
Target Class: Ubiquitin Related Biology Disease Areas: Site: Oxford Status: Official |
||
Target Class: Protein Kinase Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Miscellaneous Disease Areas: Chromatin and epigenetics Site: Toronto Status: Pending-Official Structure |
||
Target Class: Ubiquitin Related Biology Disease Areas: Site: Oxford Status: Official |
||
Target Class: Ubiquitin Related Biology, Ubiquitylation - E3 Ligases Disease Areas: Signalling Site: Toronto Status: Official |
||
Target Class: Ubiquitin Related Biology, Ubiquitylation - E3 Ligases Disease Areas: Signalling Site: Toronto Status: Official |
||
Target Class: Methyl-lysine readers Disease Areas: Cancer, Chromatin and epigenetics Site: Toronto Status: Follow-up official |
||
Target Class: Methyltransferases Disease Areas: Cancer, Chromatin and epigenetics Site: Toronto Status: Pending-Official Structure |
||
Target Class: Miscellaneous Disease Areas: Signalling Site: Toronto Status: Pending-Official Structure |
||
Target Class: Ubiquitin Related Biology, Ubiquitylation - E3 Ligases Disease Areas: Signalling Site: Toronto Status: Follow-up not counted |
||
Target Class: Miscellaneous Disease Areas: Parasitic disease Site: Toronto Status: Pending-Official Structure |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: Methyl-lysine readers Disease Areas: Chromatin and epigenetics Site: Toronto Status: Follow-up not counted |
||
Target Class: Protein Kinase Disease Areas: Cancer, Signalling, Neurobiology Site: Oxford Status: Follow-up official |
||
Target Class: Protein Kinase Disease Areas: Cancer, Signalling, Neurobiology Site: Oxford Status: Follow-up official |
||
Target Class: Protein Kinase Disease Areas: Cancer, Signalling, Neurobiology Site: Oxford Status: Follow-up official |
||
Target Class: Miscellaneous Disease Areas: Metabolism Site: Oxford Status: Pending-Official Structure |
||
Target Class: Miscellaneous Disease Areas: Metabolism Site: Oxford Status: Follow-up official |
||
Target Class: Protein Kinase Disease Areas: Cancer Site: Oxford Status: Pending-Official Structure |
||
Target Class: Protein Kinase Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Protein Kinase Disease Areas: Cancer, Signalling, Neurobiology Site: Oxford Status: Follow-up official |
||
Target Class: Poly ADP-ribose polymerase Disease Areas: Chromatin and epigenetics Site: Oxford Status: Pending-Official Structure |
||
Target Class: Miscellaneous Disease Areas: Cancer Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics, Signalling Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics, Signalling Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Cancer, Chromatin and epigenetics, Signalling Site: Oxford Status: Follow-up official |
||
Target Class: Miscellaneous Disease Areas: Site: Oxford Status: Pending-Official Structure |
||
Target Class: Bromodomain Disease Areas: Chromatin and epigenetics Site: Oxford Status: Follow-up official |
||
Target Class: Bromodomain Disease Areas: Site: Oxford Status: Follow-up official |
||
Target Class: Miscellaneous Disease Areas: Site: Oxford Status: Pending-Official Structure |
||
Target Class: Oxidoreductases Disease Areas: Site: Oxford Status: Follow-up official |
||
Target Class: Membrane proteins Disease Areas: Site: Oxford Status: Follow-up official |
||
Target Class: Membrane proteins Disease Areas: Site: Oxford Status: Follow-up official |
||
Target Class: Membrane proteins Disease Areas: Site: Oxford Status: Follow-up official |
||